Literature DB >> 8601783

Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae.

K J Hofmann1, M P Neeper, H Z Markus, D R Brown, M Müller, K U Jansen.   

Abstract

The major capsid protein L1 of human papillomaviruses (HPVs) has been identified as a promising candidate antigen for a prophylactic HPV vaccine. Since amino acid sequence heterogeneity has been demonstrated for the L1 genes within individual HPV types, nucleotide sequences of L1 were determined from six HPV-18 clinical isolates and the cervical carcinoma cell line SW756 and compared to the published HPV-18 prototype sequence. The sequences were almost identical between the clinical isolates and SW756 but differed markedly from the published prototype sequence. Resequencing the prototype HPV-18 revealed that these differences were due to sequencing artifacts of the prototype HPV-18 sequence archived in GenBank. Thus, the HPV-18 L1 genes seem to display a very high level of sequence conservation. The HPV-18 L1 gene derived from SW756 was expressed in Saccharomyces cerevisiae and self-assembly of the L1 protein into virus-like particles was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8601783     DOI: 10.1099/0022-1317-77-3-465

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Human papillomavirus 6 seropositivity is associated with risk of head and neck squamous cell carcinoma, independent of tobacco and alcohol use.

Authors:  C S Furniss; M D McClean; J F Smith; J Bryan; K M Applebaum; H H Nelson; M R Posner; K T Kelsey
Journal:  Ann Oncol       Date:  2008-12-15       Impact factor: 32.976

2.  Saccharomyces cerevisiae is permissive for replication of bovine papillomavirus type 1.

Authors:  Kong-Nan Zhao; Ian H Frazer
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18.

Authors:  Dennis Dias; Jeff Van Doren; Sonela Schlottmann; Sheri Kelly; Derek Puchalski; Wanda Ruiz; Patricia Boerckel; Joseph Kessler; Joseph M Antonello; Tina Green; Martha Brown; Judith Smith; Narendra Chirmule; Eliav Barr; Kathrin U Jansen; Mark T Esser
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

4.  Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay.

Authors:  David Opalka; Charles E Lachman; Stefani A MacMullen; Kathrin U Jansen; Judith F Smith; Narendra Chirmule; Mark T Esser
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

Review 5.  Immunomanipulative strategies for the control of human papillomavirus associated cervical disease.

Authors:  R W Tindle
Journal:  Immunol Res       Date:  1997       Impact factor: 4.505

6.  Trans-packaging of human immunodeficiency virus type 1 genome into Gag virus-like particles in Saccharomyces cerevisiae.

Authors:  Naoki Tomo; Toshiyuki Goto; Yuko Morikawa
Journal:  Microb Cell Fact       Date:  2013-03-26       Impact factor: 5.328

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.